We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Generic Pharmaceutical Association (GPhA) took the Congressional Budget Office (CBO) to task this week for its recent letter to Sen. Charles Schumer (D-N.Y.), in which CBO downplayed potential consequences of raising the drug rebates paid by generic drug manufacturers to the Medicaid program.
Senate Democrats are reaching out to Republican conferees in an effort to defeat a controversial liability waiver for vaccine producers that is likely to be placed in the fiscal year 2006 Department of Defense Appropriations Act, Hill staffers say.
In a recent report, the Government Accountability Office (GAO) faults several federal agencies for not doing enough to stem prescription drug importation, arguing that Congress should consider legislative changes to existing notification requirements and that the government needs to better coordinate its efforts.
Two influential Senate Republicans offered an amendment to a federal spending bill yesterday calling for nearly $4 billion in funding for pandemic flu preparation.
Congress' recent acceptance of language requiring notification of an FDA advisory panel's conflicts of interest signals a defeat for lawmakers, including Rep.
Efforts in both Houses to cut at least $10 billion from Medicare and Medicaid face uphill battles, as observers from nearly all sides — including conservatives, liberals, pharmaceutical firms and public interest groups — have expressed reservations about
the plans.
The HHS Inspector General (IG) has agreed to investigate the reasons behind former FDA Commissioner Lester Crawford’s sudden resignation in response to inquiries from a bipartisan coalition of lawmakers.
A broad coalition of drug purchasers, insurance companies and trade associations is challenging a provision in a draft bioterrorism bill that would extend drug patents, arguing that the language would greatly increase costs by limiting the development of generic alternatives.
The medical device industry has praised the Bush administration’s selection of Andrew von Eschenbach to become acting FDA commissioner, noting his prior career as a cancer surgeon gives him a real-world appreciation of the value of advanced medical technology.
Faster drug approvals haven’t led to more safety-related drug withdrawals, says a study by the Tufts Center for the Study of Drug Development (CSDD), even as critics decry the FDA for not protecting consumers in the wake of the Vioxx scandal.